Success Metrics

Clinical Success Rate
62.5%

Based on 5 completed trials

Completion Rate
63%(5/8)
Active Trials
0(0%)
Results Posted
160%(8 trials)
Terminated
3(30%)

Phase Distribution

Ph phase_2
4
40%
Ph not_applicable
1
10%
Ph phase_3
3
30%
Ph phase_1
1
10%
Ph phase_4
1
10%

Phase Distribution

1

Early Stage

4

Mid Stage

4

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
1(10.0%)
Phase 2Efficacy & side effects
4(40.0%)
Phase 3Large-scale testing
3(30.0%)
Phase 4Post-market surveillance
1(10.0%)
N/ANon-phased studies
1(10.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

55.6%

5 of 9 finished

Non-Completion Rate

44.4%

4 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(5)
Terminated(4)
Other(1)

Detailed Status

Completed5
Terminated3
Withdrawn1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
62.5%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (10.0%)
Phase 24 (40.0%)
Phase 33 (30.0%)
Phase 41 (10.0%)
N/A1 (10.0%)

Trials by Status

withdrawn110%
unknown110%
completed550%
terminated330%

Recent Activity

Clinical Trials (10)

Drug Details

Intervention Type
DRUG
Total Trials
10